As hypoxic-injured EC cells are frequently observed in cardiovascular disease and diabetes, it would be interesting to examine whether patients with cardiovascular disease and diabetes respond better to PI3K inhibitors or a microtubular stabilizer in clinical trials. Here, PIK3CD is linked to cardiovascular disorder.